Chemotherapy Toxicity and Dosing: The Narrow Line Between Help and Harm

Why chemotherapy is toxic at all

Classic cytotoxic drugs attack cells that divide. That is their entire strategy — hit DNA, or the machinery of copying it, so that a cell trying to divide dies instead. It is a brilliant idea with one fatal flaw: cancer cells are not the only fast-dividing cells in the body. Several NORMAL tissues renew themselves constantly, and they take the collateral damage. The bone marrow (which makes blood cells), the lining of the gut (mouth to anus), the hair follicles, and the gonads (making sperm and eggs) are all rapidly proliferating — so they are all in the line of fire. Predict the toxicity of a cytotoxic drug and you are really just naming those four tissues.

This is also why targeted therapies and immunotherapies (covered in their own chapters) were such a leap: they aim at something specific to the cancer instead of "anything dividing," so their side-effect profile is completely different. But for the classic cytotoxics, toxicity is not a surprise or a defect — it is the predictable shadow of the mechanism. That predictability is exactly what lets us plan around it.

The nadir: why timing is everything

The most important and most treacherous toxicity is myelosuppression (suppression of the bone marrow). After a dose, blood counts do not fall immediately — the cells already in circulation live out their normal lifespan. But behind them the marrow has stopped producing replacements. So counts drift down over days and reach their lowest point — the NADIR — typically around day 7 to 14 for neutrophils, then recover as the marrow restarts. At the nadir the patient is at maximum risk: neutropenia (low neutrophils) means infection can turn lethal fast, anaemia (low red cells) brings fatigue, and thrombocytopenia (low platelets) brings bleeding.

This is the core teaching of the opening scene. The patient feels worst not when the drug goes in, but roughly a week to two later, when the count is at its lowest. That is why cycles are spaced (often every 3 weeks): the gap lets the marrow recover before the next hit. And it is why a fever during the nadir — febrile neutropenia — is a medical emergency, treated with immediate broad-spectrum antibiotics before you even know the source, because a neutropenic patient cannot mount their own defence. Knowing the expected nadir day for a regimen lets you check counts at the right moment and warn the patient exactly when to worry.

The rest of the predictable toxicities

Walk the same logic through the other fast-dividing tissues and the side-effect list writes itself. The gut lining gives mucositis (painful mouth and gut ulceration) and diarrhoea. The hair follicles give alopecia (hair loss), which is distressing but reversible. The gonads give infertility, which may be permanent — and that is a conversation that must happen BEFORE treatment, not after. Nausea and vomiting are so common they get their own supportive chapter. And over the long term, cytotoxics carry two heavier shadows: reduced fertility, and a small but real risk of a second cancer (a treatment-induced malignancy years later, especially leukaemia after alkylating agents).

Layered on top of these general toxicities are the ORGAN-SPECIFIC, often CUMULATIVE ones — where the damage depends on the total lifetime dose, not just today's. These are the signposts you memorise per drug class: anthracyclines (like doxorubicin) damage the heart, and the risk climbs with cumulative dose; bleomycin scars the lungs (pulmonary fibrosis); cisplatin poisons the kidneys and the hearing (nephrotoxic and ototoxic); vincristine injures peripheral nerves (neuropathy). Each is detailed in its own class chapter — here, just know that some toxicities have a ceiling you must not cross over a lifetime.

Dosing with a ruler: BSA and the Calvert formula

You never dose a cytotoxic drug as a flat number of milligrams. Most chemotherapy is dosed by body surface area (BSA), in milligrams per square metre (mg/m²). BSA is calculated from the patient's height and weight, and it correlates better with blood volume, cardiac output and drug handling than weight alone. So a nurse does not draw up "500 mg" — she draws up "500 mg/m²" multiplied by that specific patient's BSA. This precision is not fussiness: because the therapeutic window is so narrow, a modest error in dose is the difference between an ineffective treatment and a dangerous overdose.

One important drug is dosed differently: carboplatin. Because it is cleared almost entirely by the kidneys, dosing it by BSA is too crude — a patient with poor renal function would accumulate it to toxic levels. Instead we use the Calvert formula, which sets the dose from a target drug exposure (AUC, the area under the concentration–time curve) and the patient's renal function: dose = target AUC × (GFR + 25). In plain terms, you decide how much total drug exposure you want, then work backwards through the kidneys' clearing capacity to get the milligrams. Better kidneys tolerate more; worse kidneys get less. This is pharmacokinetics applied at the bedside (see the Excretion chapter for GFR and renal clearance).

The narrow therapeutic index, and how we steer inside it

For most drugs the gap between an effective dose and a toxic one is comfortable. For cytotoxics it is razor-thin — this is a classic example of a narrow therapeutic index (see the Pharmacodynamics chapter for the therapeutic-index concept). The full dose that best kills the cancer is often close to the dose that seriously harms the patient. So oncology does not just pick a dose once and walk away; it steers continuously, using two levers guided by the nadir counts and organ function.

The two levers are dose reduction and dose delay. If the previous cycle produced a dangerously deep nadir, or the counts have not recovered in time, or an organ is showing strain (rising creatinine, falling ejection fraction), the next dose is reduced by a set percentage or delayed until recovery. Toxicity is not a reason to abandon treatment — it is feedback that tells you how to adjust the next cycle. Good oncology is a conversation between the tumour's response and the patient's tolerance, read cycle by cycle off the blood counts and the organ tests.

Handling the drug, and when it leaks: extravasation

Because cytotoxics damage any dividing cell, they are hazardous to the staff who prepare and give them, not only to the patient. Safe handling is a real discipline: drugs are mixed in special biological safety cabinets, staff wear protective gowns and gloves, spills have dedicated kits, and waste is segregated — all to prevent chronic low-dose exposure to people who handle cytotoxics every day. The Supportive care chapters cover this in full; the principle to carry is that these are hazardous materials, treated as such from pharmacy to bedside.

One acute emergency deserves its own paragraph. Extravasation is when a drug being infused LEAKS out of the vein into the surrounding tissue. For many drugs that is a minor irritation, but for vesicants — drugs that blister and kill tissue, classically the anthracyclines (doxorubicin) and the vinca alkaloids (vincristine) — extravasation can cause deep tissue necrosis, ulceration that will not heal, and sometimes surgery. Recognition is the whole game: pain, burning, swelling, or redness at the infusion site, or the infusion slowing or stopping. The first steps are to STOP the infusion immediately, leave the cannula in place and aspirate what you can, then follow the drug-specific protocol (cold or warm compresses and, for some agents, a specific antidote). Treating an extravasation like an ordinary bruise — "it's just a bit of swelling" — is how a reversible event becomes a surgical one.